Amit Kalra, MD
Gastroenterology · Gurnee, ILNPI 1215120274
Payments from drug & device makers
Across 791 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Pfizer$860
- Bristol Myers Squibb$437
- plus $4K from 32 others
What the payments were for
- Speaking & faculty fees$1,80012%
- Travel & lodging$140%
- Food & beverage$12,34186%
- Education$2742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 113 | $3,363 |
| Johnson & Johnson | 177 | $2,829 |
| Takeda Pharmaceuticals U.S.A., Inc. | 156 | $2,021 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 66 | $1,022 |
| Pfizer | 58 | $860 |
| Bristol Myers Squibb | 32 | $437 |
| Ardelyx, Inc. | 24 | $422 |
| Phathom Pharmaceuticals, Inc. | 17 | $405 |
| Regeneron Healthcare Solutions, Inc. | 15 | $362 |
| Sanofi | 9 | $256 |
| Gilead | 19 | $227 |
| QOL Medical, LLC | 8 | $202 |
| Lilly USA, LLC | 13 | $200 |
| Madrigal Pharmaceuticals | 8 | $190 |
| Sonendo Inc | 2 | $169 |
| Ipsen Biopharmaceuticals, Inc | 6 | $157 |
| Braintree Laboratories, Inc. | 9 | $133 |
| Ironwood Pharmaceuticals, Inc | 7 | $128 |
| Celltrion USA Inc. | 7 | $124 |
| Intercept Pharmaceuticals, Inc. | 8 | $121 |
| Janssen Scientific Affairs, LLC | 1 | $116 |
| Daiichi Sankyo Inc. | 5 | $111 |
| Pentax Of America, Inc. | 2 | $81 |
| Evoke Pharma, Inc. | 4 | $74 |
| Merck | 4 | $72 |
| Fresenius Kabi USA, LLC | 3 | $72 |
| Organon | 2 | $53 |
| Tersera Therapeutics LLC | 1 | $36 |
| Boston Scientific | 1 | $33 |
| W. L. Gore & Associates, Inc. | 2 | $33 |
| Laborie Medical Technologies Corp. | 1 | $23 |
| UCB, Inc. | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $16 |
| Amgen | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Vivus LLC | 2 | $14 |
| Gastrogpo, LLC | 4 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINZESS$1,800
- VIBERZI$1,400
- GentleWave G4 Console$154
- VOQUEZNA$133
- STELARA$116
How this compares
$14,429 in reported general payments places this provider in the 80th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 40 | $60,207 |
| CreonLipase/Protease/Amylase | 21 | $47,108 |
| Mesalamine | 24 | $11,093 |
| EliquisApixaban | 12 | $7,894 |
| XareltoRivaroxaban | 13 | $7,424 |
| Budesonide EcBudesonide | 11 | $7,047 |
| Budesonide DrBudesonide | 16 | $4,272 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 51 | $3,340 |
| Omeprazole | 235 | $3,219 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 14 | $2,310 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 149 | $2,298 |
| Pantoprazole Sodium | 134 | $1,606 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 68 | $1,137 |
| Famotidine | 55 | $616 |
| Lactulose | 13 | $556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $3,363 | $107,31561 claims |
| PfizerEliquis | $860 | $7,89412 claims |
| Johnson & JohnsonXarelto | $2,829 | $7,42413 claims |
| Braintree Laboratories, Inc.Sutab | $133 | $2,31014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 787 gastroenterology providers in Illinois.
Other gastroenterology in Gurnee
- Jonathan RosenbergGurnee$3.1M
- Fred RosenbergGurnee$318K
- Kamran AyubOak Lawn$4.3M
- David RubinChicago$3.6M
- Stephen HanauerChicago$2.9M
- Parambir DulaiChicago$2.2M
- Charles BerkelhammerOak Lawn$1.9M
- Ikuo HiranoChicago$1.8M
- Manish BhuvaLake Barrington$1.7M
- Steven FlammChicago$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.